Hypotony Maculopathy Related to Anti-VEGF Intravitreal Injection
Mário Lima-Fontes,Gonçalo Godinho,Ana Maria Cunha,Carolina Madeira,Manuel Falcão,Fernando Falcão-Reis,Ângela Carneiro
DOI: https://doi.org/10.2147/IMCRJ.S382421
2022-09-20
International Medical Case Reports Journal
Abstract:Mário Lima-Fontes, 1 Gonçalo Godinho, 2 Ana Maria Cunha, 1 Carolina Madeira, 3 Manuel Falcão, 1, 4 Fernando Falcão-Reis, 1, 4 Ângela Carneiro 1, 4 1 Department of Ophthalmology, Centro Hospitalar Universitário São João, Porto, Portugal; 2 Department of Ophthalmology, Centro Hospitalar de Leiria, Leiria, Portugal; 3 Department of Ophthalmology, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; 4 Department of Surgery and Physiology, Faculty of Medicine, University of Porto, Porto, Portugal Correspondence: Mário Lima-Fontes, Department of Ophthalmology, Centro Hospitalar Universitário São João, Alameda Professor Hernâni Monteiro, Porto, 4200-319, Portugal, Tel +351 918420563, Fax +351 225513669, Email Purpose: To describe a case of hypotony maculopathy following anti-VEGF intravitreal injection (IVI) in a patient with pseudoxanthoma elasticum (PE). Methods: Clinical case report. Results: A 52-year-old male complained of right eye (OD) vision loss 2 days after an uncomplicated anti-VEGF IVI for the treatment of choroidal neovascularization secondary to angioid streaks. Relevant medical history included PE, pathologic myopia, and a previous pars plana vitrectomy (PPV) due to a retinal detachment. OD best-corrected visual acuity (BCVA) dropped from 6/12 to 6/18 after the IVI. Intraocular pressure (IOP) was 3 mmHg and chorioretinal folds were evident in the posterior pole. Topical dexamethasone and atropine were prescribed, and full recovery was noticed after 3 days. Four months later, the patient developed a new episode of vision loss after another IVI. His BCVA was counting fingers, IOP was 2mmHg, and more noticeable chorioretinal folds were found. This time, an open scleral wound at the injection site was evident and a scleral suture was necessary. Once again, the patient recovered well. Conclusion: Hypotony maculopathy following intravitreal injection is a rare condition. However, the described patient presented several conditions which could be related with poor scleral wound closure: intrinsic scleral fragility due to myopia and pseudoxanthoma elasticum; repeated IVI procedures; and absence of vitreous in the posterior segment due to prior vitrectomy. Despite the good outcome, hypotony maculopathy may be a sight-threatening condition, and special attention is necessary for specific patients with risk factors. Keywords: hypotony maculopathy, intravitreal injection, anti-VEGF, pseudoxanthoma elasticum, angioid streaks Pseudoxanthoma elasticum (PE) is an autosomal recessive disease linked to a mutation in the ABCC6 gene. It causes fragmentation and calcification of the elastic fibers, generating dermatological, vascular, and ophthalmological malformations. The deterioration of the Bruch membrane's elastic fibers creates angioid streaks, which can develop choroidal neovascularization (CNV). 1 Anti-VEGF intravitreal injection (IVI) is commonly used to treat retinal conditions as CNV or diabetic macular edema. Despite being a safe procedure, several IVI are usually necessary to improve or preserve best-corrected visual acuity (BCVA) increasing the risk of adverse effects. Hypotony maculopathy has been described as the eye globe low pressure that leads to anatomical and functional changes. The most common cause is glaucoma filtering surgery. 2 Despite the previous descriptions of wound leaks due to IVI, 3,4 the relation with hypotony maculopathy is not usual. We aim to report a case of a hypotony maculopathy following an anti-VEGF intravitreal injection. Description of a clinical case of hypotony maculopathy following anti-VEGF IVI in a patient with pseudoxanthoma elasticum and CNV secondary to angioid streaks. Written informed consent for publication of this clinical case report was obtained from the patient. Institutional approval was required to publish the case details. A 52-years-old male presented visual acuity loss of his right eye (OD) 2 days after an uncomplicated ranibizumab IVI with a 30G needle. The past medical history included PE, high myopia, and OD pars plana vitrectomy due to retinal detachment. He was being treated with monthly ranibizumab due to choroidal neovascularization secondary to angioid streaks, with 78 previous injections in the OD. At presentation, his BCVA was 6/18 and the intraocular pressure (IOP) was 3 mmHg. Slit-lamp examination of the anterior segment was unremarkable. Fundoscopy and OCT-scans revealed posterior pole chorioretinal folds (Figure 1A). Altogether, the low intraocular pressure and fundoscopic findings led to the diagnosis of hypotony maculopathy. Topical dexamethasone and atropine were pres -Abstract Truncated-